These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17277961)

  • 41. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P; Nguyen H; Barbier A; Baron R
    J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Bisphosphonates in osteoporosis therapy. Standards and perspectives].
    Reinsdorf S; Habermann B; Hochmuth K; Kurth AA
    Orthopade; 2007 Feb; 36(2):110-7. PubMed ID: 17252258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
    Polyzos SA; Anastasilakis AD; Makras P; Terpos E
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of amorphous pyrophosphate on calcium phosphate cement resorption and bone generation.
    Grover LM; Wright AJ; Gbureck U; Bolarinwa A; Song J; Liu Y; Farrar DF; Howling G; Rose J; Barralet JE
    Biomaterials; 2013 Sep; 34(28):6631-7. PubMed ID: 23747007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis.
    Matsumoto T; Nagase Y; Iwasawa M; Yasui T; Masuda H; Kadono Y; Nakamura K; Tanaka S
    Arthritis Rheum; 2011 Dec; 63(12):3908-17. PubMed ID: 21898348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bisphosphonates use in children.
    Sebestyen JF; Srivastava T; Alon US
    Clin Pediatr (Phila); 2012 Nov; 51(11):1011-24. PubMed ID: 22935217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
    Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis of ATP derivatives of compounds of the mevalonate pathway (isopentenyl di- and triphosphate; geranyl di- and triphosphate, farnesyl di- and triphosphate, and dimethylallyl diphosphate) catalyzed by T4 RNA ligase, T4 DNA ligase and other ligases Potential relationship with the effect of bisphosphonates on osteoclasts.
    Sillero MA; de Diego A; Tavares JE; Silva JA; Pérez-Zúñiga FJ; Sillero A
    Biochem Pharmacol; 2009 Aug; 78(4):335-43. PubMed ID: 19414000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experimental basis for the use of bisphosphonates in Paget's disease of bone.
    Fleisch H
    Clin Orthop Relat Res; 1987 Apr; (217):72-8. PubMed ID: 3549097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton.
    Rogers MJ; Mönkkönen J; Munoz MA
    Bone; 2020 Oct; 139():115493. PubMed ID: 32569873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism.
    Fleisch H
    Recent Results Cancer Res; 1989; 116():1-28. PubMed ID: 2669065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pharmacokinetics of bisphosphonate.].
    Nakamura M; Koide M; Udagawa N
    Clin Calcium; 2016; 26(11):1561-1570. PubMed ID: 27777389
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in understanding the mechanism of action of bisphosphonates.
    Coxon FP; Thompson K; Rogers MJ
    Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis.
    Altundag O; Altundag K; Selim Silay Y; Gunduz M; Demircan K; Gullu I
    Med Hypotheses; 2004; 63(6):1010-3. PubMed ID: 15504568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
    Rogers MJ
    Calcif Tissue Int; 2004 Dec; 75(6):451-61. PubMed ID: 15332174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.
    Hughes DE; MacDonald BR; Russell RG; Gowen M
    J Clin Invest; 1989 Jun; 83(6):1930-5. PubMed ID: 2524504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.